The medical device manufacturing sector is undergoing a seismic shift, with automation emerging as the cornerstone of innovation and efficiency as the industry looks toward 2035, driven by the urgent need to meet rising global healthcare demands. Projections from recent market analyses indicate
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose extensive experience in research, development, and innovation has positioned him as a thought leader in the cell and gene therapy (CGT) industry. With a sharp focus on emerging technologies and strategic growth, Ivan
In a nation where millions of Americans ration life-saving medications due to staggering costs, and communities yearn for stable, high-paying jobs, one pharmaceutical giant is stepping up with a groundbreaking plan. AstraZeneca, a global leader in healthcare, has struck a historic agreement with
I'm thrilled to sit down with Ivan Kairatov, a renowned expert in biopharma with a wealth of experience in research and development, particularly in the rapidly evolving field of cell and gene therapies (CGTs). With his deep knowledge of technology and innovation in the industry, Ivan offers unique
Imagine a biopharmaceutical production line where every process, from drug formulation to final packaging, is mirrored in a virtual environment that predicts failures before they occur, optimizes workflows in real time, and slashes development costs by millions. This isn’t a distant dream but the
Imagine a region where the demand for life-changing biopharmaceuticals is skyrocketing, yet the race to deliver these treatments faster and more efficiently is becoming increasingly competitive. Asia, with its dynamic healthcare landscape, stands at the forefront of this challenge, particularly in
